Literature DB >> 35110333

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis.

Joanna C Robson1, Peter C Grayson2, Cristina Ponte3, Ravi Suppiah4, Anthea Craven5, Andrew Judge6,7, Sara Khalid5, Andrew Hutchings8, Richard A Watts5,9, Peter A Merkel10, Raashid A Luqmani5.   

Abstract

OBJECTIVE: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA).
METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate criteria items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.
RESULTS: The development set for GPA consisted of 578 cases of GPA and 652 comparators. The validation set consisted of an additional 146 cases of GPA and 161 comparators. From 91 candidate items, regression analysis identified 26 items for GPA, 10 of which were retained. The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting or sino-nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1); cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti-proteinase 3 ANCA positivity (+5); pulmonary nodules, mass or cavitation on chest imaging (+2); granuloma or giant cells on biopsy (+2); inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1); pauci-immune glomerulonephritis (+1); perinuclear ANCA or antimyeloperoxidase ANCA positivity (-1); and eosinophil count ≥1×109 /L (-4). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having GPA if the cumulative score was ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 93% (95% CI 87% to 96%) and the specificity was 94% (95% CI 89% to 97%).
CONCLUSION: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for GPA demonstrate strong performance characteristics and are validated for use in research. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arthritis; granulomatosis with polyangiitis; rehabilitation

Mesh:

Substances:

Year:  2022        PMID: 35110333     DOI: 10.1136/annrheumdis-2021-221795

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   27.973


  10 in total

1.  Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy.

Authors:  Yong Zhong; Xiangcheng Xiao; Qi Xiong; Wei Lin; Chanjuan Shen; Ting Meng; Rong Tang; Joshua D Ooi; Peter J Eggenhuizen; Jinbiao Chen; Wannian Nie; Xia Li; Qiaoling Zhou; Ping Xiao
Journal:  Immunol Res       Date:  2022-10-13       Impact factor: 4.505

Review 2.  Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

Authors:  Adél Molnár; Péter Studinger; Nóra Ledó
Journal:  Front Med (Lausanne)       Date:  2022-06-03

Review 3.  Global epidemiology of vasculitis.

Authors:  Richard A Watts; Gulen Hatemi; Jane C Burns; Aladdin J Mohammad
Journal:  Nat Rev Rheumatol       Date:  2021-12-01       Impact factor: 20.543

4.  Clinical Significance of Antineutrophil Cytoplasmic Antibody Positivity in Patients Infected with SARS-CoV-2.

Authors:  Lucy Eunju Lee; Wooyong Jeong; Yong-Beom Park; Su Jin Jeong; Sang-Won Lee
Journal:  J Clin Med       Date:  2022-07-17       Impact factor: 4.964

Review 5.  The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs.

Authors:  Yasutaka Kimoto; Takahiko Horiuchi
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

6.  The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.

Authors:  Allyson C Egan; Andreas Kronbichler; Irmgard Neumann; Alessandra Bettiol; Nicholas Carlson; Maria C Cid; Giacomo Emmi; Seerapani Gopaluni; Lorraine Harper; Thomas Hauser; Mark A Little; Raashid A Luqmani; Alfred Mahr; Mark McClure; Aladdin J Mohammad; Karl Emil Nelveg-Kristensen; Sophie Ohlsson; Chen Au Peh; Matthew Rutherford; Beatriz Sanchez Alamo; Jennifer Scott; Mårten Segelmark; Rona M Smith; Wladimir M Szpirt; Gunnar Tomasson; Giorgio Trivioli; Augusto Vaglio; Michael Walsh; Maria Wester Trejo; Kerstin Westman; Ingeborg M Bajema; David R W Jayne
Journal:  Kidney Int Rep       Date:  2022-05-25

Review 7.  Environmental factors influencing the risk of ANCA-associated vasculitis.

Authors:  Wen-Man Zhao; Zhi-Juan Wang; Rui Shi; Yu-Yu Zhu; Sen Zhang; Rui-Feng Wang; De-Guang Wang
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

8.  Autoimmune Diseases Induced or Exacerbated by COVID-19: A Single Center Experience.

Authors:  Yuval Ishay; Ariel Kenig; Limor Rubin; Oded Shamriz; Fadi Kharouf
Journal:  Autoimmune Dis       Date:  2022-09-06

9.  Clinical Significance of MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis: Experience From a Longitudinal Chinese Cohort.

Authors:  Suying Liu; Linna Han; Yanhui Liu; Jun Yang; Yu Zhang; Mengtao Li; Xinping Tian; Xiaofeng Zeng; Li Wang; Fengchun Zhang
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

Review 10.  Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management.

Authors:  Shangqing Ge; Xingyu Zhu; Qinyao Xu; Junyan Wang; Cheng An; Ying Hu; Fan Yang; Xinyi Wang; Yipin Yang; Shuwen Chen; Ruimin Jin; Haiyan Li; Xinchen Peng; Yue Liu; Junnan Xu; Minhui Zhu; Zongwen Shuai
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.